Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma

Jie Sheng Chu, Fei Jiao Ge, Bo Zhang, Yan Wang, Nicola Silvestris, Lie Jun Liu, Chuan Hua Zhao, Li Lin, Anna Elisabetta Brunetti, Ya Li Fu, Jun Wang, Angelo Paradiso, Jian Ming Xu

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background: We explore the clinical and prognostic significance of expression of vascular endothelial growth factor receptor (VEGFR)-2, platelet-derived growth factor receptor (PDGFR)-β, and c-Met in patients with hepatocellular carcinoma (HCC). Methods. The expression of VEGFR-2, PDGFR-β, and c-Met were determined by immunohistochemical examination of the tissues of 93 HCC patients. The relationships of these markers with clinicopathological factors and prognosis were then analyzed. Results: High expression of VEGFR-2, PDGFR-β, and c-Met was found in 86%, 19.4%, and 80.6% of patients, respectively. Expression of VEGFR-2 correlated with gender (P = 0.044), hepatitis B surface antigen positivity (P = 0.024), degree of tumor differentiation (P = 0.023), and hepatic cirrhosis (P = 0.026). Expression of PDGFR-β correlated with alpha-fetoprotein level (P = 0.029), tumor size (P = 0.033), and hepatic cirrhosis (P = 0.023). No significant correlations were identified between expression of c-Met and clinicopathological factors. Expression of PDGFR-β correlated with overall survival (P = 0.046) and expression of c-Met correlated with progression-free survival (P = 0.01). Conclusions: We found that in patients with HCC, high expression of VEGFR-2 correlates with chronic hepatitis B virus infection and hepatic cirrhosis. High expression of PDGFR-β is a predictor of poor prognosis. High expression of C-Met may predict therapeutic effectiveness of sorafenib in HCC patients.

Original languageEnglish
Article number16
JournalJournal of Experimental and Clinical Cancer Research
Volume32
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

Platelet-Derived Growth Factor Receptors
Vascular Endothelial Growth Factor Receptor-2
Hepatocellular Carcinoma
Liver Cirrhosis
Chronic Hepatitis B
alpha-Fetoproteins
Virus Diseases
Hepatitis B Surface Antigens
Hepatitis B virus
Disease-Free Survival
Neoplasms
Survival

Keywords

  • c-Met
  • Hepatocellular carcinoma
  • PDGFR-β
  • Sorafenib
  • Survival analysis
  • VEGFR-2

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. / Chu, Jie Sheng; Ge, Fei Jiao; Zhang, Bo; Wang, Yan; Silvestris, Nicola; Liu, Lie Jun; Zhao, Chuan Hua; Lin, Li; Brunetti, Anna Elisabetta; Fu, Ya Li; Wang, Jun; Paradiso, Angelo; Xu, Jian Ming.

In: Journal of Experimental and Clinical Cancer Research, Vol. 32, No. 1, 16, 2013.

Research output: Contribution to journalArticle

Chu, Jie Sheng ; Ge, Fei Jiao ; Zhang, Bo ; Wang, Yan ; Silvestris, Nicola ; Liu, Lie Jun ; Zhao, Chuan Hua ; Lin, Li ; Brunetti, Anna Elisabetta ; Fu, Ya Li ; Wang, Jun ; Paradiso, Angelo ; Xu, Jian Ming. / Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. In: Journal of Experimental and Clinical Cancer Research. 2013 ; Vol. 32, No. 1.
@article{2051e36f3a3047ff93ff93a5a47f04ec,
title = "Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma",
abstract = "Background: We explore the clinical and prognostic significance of expression of vascular endothelial growth factor receptor (VEGFR)-2, platelet-derived growth factor receptor (PDGFR)-β, and c-Met in patients with hepatocellular carcinoma (HCC). Methods. The expression of VEGFR-2, PDGFR-β, and c-Met were determined by immunohistochemical examination of the tissues of 93 HCC patients. The relationships of these markers with clinicopathological factors and prognosis were then analyzed. Results: High expression of VEGFR-2, PDGFR-β, and c-Met was found in 86{\%}, 19.4{\%}, and 80.6{\%} of patients, respectively. Expression of VEGFR-2 correlated with gender (P = 0.044), hepatitis B surface antigen positivity (P = 0.024), degree of tumor differentiation (P = 0.023), and hepatic cirrhosis (P = 0.026). Expression of PDGFR-β correlated with alpha-fetoprotein level (P = 0.029), tumor size (P = 0.033), and hepatic cirrhosis (P = 0.023). No significant correlations were identified between expression of c-Met and clinicopathological factors. Expression of PDGFR-β correlated with overall survival (P = 0.046) and expression of c-Met correlated with progression-free survival (P = 0.01). Conclusions: We found that in patients with HCC, high expression of VEGFR-2 correlates with chronic hepatitis B virus infection and hepatic cirrhosis. High expression of PDGFR-β is a predictor of poor prognosis. High expression of C-Met may predict therapeutic effectiveness of sorafenib in HCC patients.",
keywords = "c-Met, Hepatocellular carcinoma, PDGFR-β, Sorafenib, Survival analysis, VEGFR-2",
author = "Chu, {Jie Sheng} and Ge, {Fei Jiao} and Bo Zhang and Yan Wang and Nicola Silvestris and Liu, {Lie Jun} and Zhao, {Chuan Hua} and Li Lin and Brunetti, {Anna Elisabetta} and Fu, {Ya Li} and Jun Wang and Angelo Paradiso and Xu, {Jian Ming}",
year = "2013",
doi = "10.1186/1756-9966-32-16",
language = "English",
volume = "32",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma

AU - Chu, Jie Sheng

AU - Ge, Fei Jiao

AU - Zhang, Bo

AU - Wang, Yan

AU - Silvestris, Nicola

AU - Liu, Lie Jun

AU - Zhao, Chuan Hua

AU - Lin, Li

AU - Brunetti, Anna Elisabetta

AU - Fu, Ya Li

AU - Wang, Jun

AU - Paradiso, Angelo

AU - Xu, Jian Ming

PY - 2013

Y1 - 2013

N2 - Background: We explore the clinical and prognostic significance of expression of vascular endothelial growth factor receptor (VEGFR)-2, platelet-derived growth factor receptor (PDGFR)-β, and c-Met in patients with hepatocellular carcinoma (HCC). Methods. The expression of VEGFR-2, PDGFR-β, and c-Met were determined by immunohistochemical examination of the tissues of 93 HCC patients. The relationships of these markers with clinicopathological factors and prognosis were then analyzed. Results: High expression of VEGFR-2, PDGFR-β, and c-Met was found in 86%, 19.4%, and 80.6% of patients, respectively. Expression of VEGFR-2 correlated with gender (P = 0.044), hepatitis B surface antigen positivity (P = 0.024), degree of tumor differentiation (P = 0.023), and hepatic cirrhosis (P = 0.026). Expression of PDGFR-β correlated with alpha-fetoprotein level (P = 0.029), tumor size (P = 0.033), and hepatic cirrhosis (P = 0.023). No significant correlations were identified between expression of c-Met and clinicopathological factors. Expression of PDGFR-β correlated with overall survival (P = 0.046) and expression of c-Met correlated with progression-free survival (P = 0.01). Conclusions: We found that in patients with HCC, high expression of VEGFR-2 correlates with chronic hepatitis B virus infection and hepatic cirrhosis. High expression of PDGFR-β is a predictor of poor prognosis. High expression of C-Met may predict therapeutic effectiveness of sorafenib in HCC patients.

AB - Background: We explore the clinical and prognostic significance of expression of vascular endothelial growth factor receptor (VEGFR)-2, platelet-derived growth factor receptor (PDGFR)-β, and c-Met in patients with hepatocellular carcinoma (HCC). Methods. The expression of VEGFR-2, PDGFR-β, and c-Met were determined by immunohistochemical examination of the tissues of 93 HCC patients. The relationships of these markers with clinicopathological factors and prognosis were then analyzed. Results: High expression of VEGFR-2, PDGFR-β, and c-Met was found in 86%, 19.4%, and 80.6% of patients, respectively. Expression of VEGFR-2 correlated with gender (P = 0.044), hepatitis B surface antigen positivity (P = 0.024), degree of tumor differentiation (P = 0.023), and hepatic cirrhosis (P = 0.026). Expression of PDGFR-β correlated with alpha-fetoprotein level (P = 0.029), tumor size (P = 0.033), and hepatic cirrhosis (P = 0.023). No significant correlations were identified between expression of c-Met and clinicopathological factors. Expression of PDGFR-β correlated with overall survival (P = 0.046) and expression of c-Met correlated with progression-free survival (P = 0.01). Conclusions: We found that in patients with HCC, high expression of VEGFR-2 correlates with chronic hepatitis B virus infection and hepatic cirrhosis. High expression of PDGFR-β is a predictor of poor prognosis. High expression of C-Met may predict therapeutic effectiveness of sorafenib in HCC patients.

KW - c-Met

KW - Hepatocellular carcinoma

KW - PDGFR-β

KW - Sorafenib

KW - Survival analysis

KW - VEGFR-2

UR - http://www.scopus.com/inward/record.url?scp=84875657918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875657918&partnerID=8YFLogxK

U2 - 10.1186/1756-9966-32-16

DO - 10.1186/1756-9966-32-16

M3 - Article

VL - 32

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

M1 - 16

ER -